Authors:
A Murad, SJ Lewis, GD Smith, SM Collin, L Chen, FC Hamdy, DE Neal, J Donovan, RM Martin
Journal name: 
Prostate Cancer Prostatic Dis
Citation info: 
12(3):296-300
Abstract: 
Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n(cases)=1608, n(controls)=3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR(CC & GC v GG)=1.04, 95% CI=0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.
DOI: 
http://doi.org/10.1038/pcan.2009.18
Research group: 
Neal Group
E-pub date: 
31 Aug 2009